Provided by Tiger Trade Technology Pte. Ltd.

Prime Medicine, Inc.

3.57
+0.330010.19%
Post-market: 3.53-0.0400-1.12%19:58 EST
Volume:3.65M
Turnover:12.76M
Market Cap:644.42M
PE:-2.48
High:3.59
Open:3.36
Low:3.30
Close:3.24
52wk High:6.94
52wk Low:1.11
Shares:180.51M
Float Shares:99.80M
Volume Ratio:1.06
T/O Rate:3.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4387
EPS(LYR):-1.6516
ROE:-112.34%
ROA:-35.52%
PB:3.98
PE(LYR):-2.16

Loading ...

JonesTrading Sticks to Its Buy Rating for Prime Medicine, Inc. (PRME)

TIPRANKS
·
Jan 23

Prime Medicine Initiated at Outperform by LifeSci Capital

Dow Jones
·
Dec 24, 2025

LifeSci Initiates Prime Medicine at Outperform With $6 Price Target

MT Newswires Live
·
Dec 23, 2025

Prime Medicine Reports Positive Phase 1/2 Results for PM359 in Chronic Granulomatous Disease

Reuters
·
Dec 07, 2025

Prime Medicine Announces the New England Journal of Medicine Publication of Pm359 Clinical Data for the Treatment of Chronic Granulomatous Disease

THOMSON REUTERS
·
Dec 07, 2025

Stock Track | Prime Medicine (PRME) Plummets 5% Following Analyst's Cautious Hold Rating and Extended Development Timeline

Stock Track
·
Nov 13, 2025

Stock Track | Prime Medicine (PRME) Plunges 5% Following Analyst's Cautious Hold Rating

Stock Track
·
Nov 13, 2025

Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline

TIPRANKS
·
Nov 13, 2025

Prime Medicine Is Maintained at Neutral by Citigroup

Dow Jones
·
Nov 12, 2025

Stock Track | Prime Medicine Soars 5.25% as CEO Prepares to Speak at Jefferies Global Healthcare Conference

Stock Track
·
Nov 11, 2025

Prime Medicine Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 10, 2025

Prime Medicine files automatic mixed securities shelf

TIPRANKS
·
Nov 07, 2025

Prime Medicine Inc: Files for Mixed Shelf Offering - SEC Filing

THOMSON REUTERS
·
Nov 07, 2025

Prime Medicine : Sales Agreement Prospectus Covers Offer, Sale of Shares of Common Stock of up to $200 Mln From Time to Time

THOMSON REUTERS
·
Nov 07, 2025

Prime Medicine Q3 EPS $(0.32) Misses $(0.26) Estimate, Sales $1.225M Beat $1.026M Estimate

Benzinga
·
Nov 07, 2025

Prime Medicine Unveils Pipeline Progress and Clinical Milestones for Prime Editing Platform

Reuters
·
Nov 07, 2025

Prime Medicine Q3 net loss narrows

Reuters
·
Nov 07, 2025

BRIEF-Prime Medicine, Inc. Q3 EPS USD -0.32

Reuters
·
Nov 07, 2025

Prime Medicine Appoints Matthew Hawryluk as Chief Business Officer

Reuters
·
Nov 07, 2025

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

THOMSON REUTERS
·
Nov 07, 2025